List of abbreviations {#nomen0010}
=====================

LN

:   lymph node

mLNR

:   modified lymph node ratio

LNR

:   lymph node ratio

AIC

:   Akaike's Information Criterion

C-index

:   Harrell's concordance index

AJCC

:   American Joint Committee on Cancer

NPLN

:   the number of positive lymph node

LODDS

:   log odds of positive lymph nodes

NRLN

:   the number of removed lymph node

NNLN

:   the number of negative LN

SEER

:   the National Cancer Institute's Surveillance, Epidemiology, and End Results

ER

:   estrogen receptor

PR

:   progesterone receptor

IQR

:   interquartile range

RCS

:   restricted cubic spline

HR

:   hazard ratio

1. Introduction {#sec1}
===============

Breast cancer is the most common cancer and has the highest morbidity and mortality among women worldwide. According to the National Cancer Institute, more than 270,000 new cases and 42,000 deaths have been estimated in 2019 in the United States \[[@bib1]\]. ^、^Metastatic regional lymph nodes (LNs) significantly influence the prediction of long-term breast cancer prognosis after surgery \[[@bib2]\]. The traditional American Joint Committee on Cancer (AJCC) N stage is based on the number of positive lymph nodes (NPLNs) and is considered one of the most powerful prognostic factors in breast cancer \[[@bib3]\]. Although the number of metastatic LNs has been demonstrated to confer a poor prognosis, the technique of axillary lymph node dissection varies across various institutions, depending on surgical expertise, patient age and co-morbidities, handling of the surgical specimen by the pathologist \[[@bib4]\]. In this condition, in addition to the AJCC N stage, some studies have suggested that LN status should be described by lymph node positive rate (LNR) or log odds of positive lymph nodes (LODDS) \[[@bib5]\]. The LNR, a powerful prognostic predictor in breast cancer, is calculated as the NPLNs divided by the number of removed lymph nodes (NRLNs) \[[@bib6], [@bib7], [@bib8], [@bib9], [@bib10]\]. The LODDS is defined as the logarithmic value of NPLNs divided by the number of negative LNs (NNLNs) and has demonstrated prognostic superiority in other cancers such as gastric cancer \[[@bib11],[@bib12]\] and colorectal cancer \[[@bib13], [@bib14], [@bib15], [@bib16]\].

However, the existing staging systems still have some disadvantages. When NRLNs is low, the prognosis evaluation of these staging systems will be affected. For example, there is a negative correlation between NRLNs and OS in breast cancer patients with low NRLNs (often \< 10) \[[@bib17]\]. Hence, it is clinically required that a certain number of axillary LNs should be resected after a mastectomy to avoid underestimating the tumor stage \[[@bib18]\]. Apart from that, when NRLNs is too low, the variability of LNR is large, which affects its accuracy. Therefore, some studies may choose to exclude samples that do not meet a certain number of LNs \[[@bib19]\]. To solve this problem, we have proposed mLNR which is calculated by adding 2 to the denominator of LNR, or NRLNs. Then, we studied the impact of these staging systems on prognostic accuracy when there are less or more than 10 LNs removed.

In this study, we compare the prognostic performance of the conventional AJCC N stage and the ratio-based nodal staging systems (LNR, mLNR and LODDS) in breast cancer patients and investigate differences between these staging systems in low NRLNs and high NRLNs. Calculation results show that mLNR which is based on LNR increases prognostic performance especially in patients with low NRLNs.

2. Methods {#sec2}
==========

2.1. Patient selection {#sec2.1}
----------------------

The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was used in this study. We identified breast cancer patients in the SEER database according to International Classification of Diseases for Oncology, third revision (ICD-O-3) code C50 (breast). Patients with stage 0 disease were excluded. Patients with unclear LN data or bilateral breast cancer were also excluded from the analysis ([Supplementary Fig. 1](#appsec1){ref-type="sec"}).

Standard data on the demographic information, surgical information, clinical pathology and tumor-related information of each patient were extracted. The tumor-related data included tumor size, stage, presence or absence of distant metastasis, TNM stage, and estrogen receptor (ER) and progesterone receptor (PR) expression. The date of the last follow-up and the vital status were also collected for all patients. For comparative purposes, the data on LN status was categorized into several different LN staging systems: seventh edition AJCC N categories, LNR, and LODDS. To avoid infinite values for LODDS, we added 0.5 to the numerator and denominator when calculating LODDS.

We chose OS as an outcome variable in our study to compare prognostic performance between different models. OS was calculated as the length of time until death, irrespective of the cause.

2.2. Statistical analyses {#sec2.2}
-------------------------

The demographic, clinical, pathological and interventional variables were reported as percentages or medians with interquartile ranges (IQRs) or as means ± standard deviations. Univariate analysis was performed for all possible confounders using Cox models. The significant confounders (P \< 0.05) in the univariate analysis were then analyzed in the multivariate analysis. Age, race, pathological type, pathological grade, tumor size, type of surgery, and ER and PR expression were analyzed as prognostic factors. OS was estimated using the Kaplan-Meier method, and differences in survival were examined with the log-rank test. The relationship between different LN staging systems and prognosis was acquired by three-knot restricted cubic spline (RCS) functions, except for the NRLNs, which was evaluated by a four-knot RCS function.

Multivariate Cox models regarding OS were created for a limited group and a sufficient group to assess the independent prognostic value of each nodal category. To verify the selectivity and goodness-of-fit, we calculated Akaike's information criterion (AIC) and Harrell's concordance index (C-statistic) for each model. AIC illustrates the accuracy and simplicity of the model. Usually, the smaller the AIC value, the better the fit of the model. C-statistic is a generalization of the area under the receiver operating characteristic curve that quantifies the proportion of all patient pairs for whom the predicted and observed survival outcomes are concordant \[[@bib20]\]. A value of C-statistic = 0.5 indicates no predictive ability compared with chance alone, and a value of 1 indicates perfect discrimination.

Subsequently, the patients were divided into 4 LNR risk groups: LNR1 (LNR = 0), LNR2 (0 \< LNR≤0.2), LNR3 (0.2 \< LNR≤0.65) and LNR4 (LNR\>0.65). The chosen LNR cutoff values were based on a previously published analysis.^10^ The LODDS was similarly analyzed as both a continuous and a categorical variable using cutoff values based on a previously published analysis. Four groups were created based on LODDS: LODDS1 (LODDS ≤ −1.00), LODDS2 (−1.00 \< LODDS ≤ 0), LODDS3 (0 \< LODDS ≤ 1.5) and LODDS4 (LODDS\> 1.5) \[[@bib21]\]. To obtain a reasonable mLNR cutoff value, we selected 86,498 patients with positive LN metastasis in the cohort. A simple random sampling of 10,000 patients with replacement was repeated 1000 times. Both cutoffs were varied between 0.05 and 0.95 in steps of 0.05. The optimal cutoff values were defined as the pair of cutoffs that led to the greatest number of the minimal AIC values during the 1000 times of simple random sampling. Finally, we chose 0.20 and 0.50 as the cutoff values of mLNR ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Distribution of simple random sampling lymph node ratio cutoff points. The Akaike's information criterion (AIC) was used to select the optimal cutoff values in 1000 iterations.Fig. 1

All analyses were carried out with R version 3.5.2. All tests were 2-sided, and a P \< 0.05 was considered statistically significant.

Overall, 264,096 patients with breast cancer who underwent curative-intent resection and who met the inclusion criteria were identified.

3. Results {#sec3}
==========

3.1. Patient characteristics and impact on overall survival {#sec3.1}
-----------------------------------------------------------

Initially, we identified 516,898 patients who had breast cancer diagnosed between 2004 and 2010. Finally, 264,096 M0 patients, those with only one primary breast tumor, met the inclusion criteria and were enrolled in this study ([Supplementary Fig. 1](#appsec1){ref-type="sec"}). The demographic, clinical and interventional characteristics are summarized in [Table 1](#tbl1){ref-type="table"}. The ages ranged from 18 to 103 years with a median age of 59.0 years (IQR: 47--66). The patients were predominantly white (215,752, 81.2%), and of the remaining patients, 23,839 (9.0%) were black, and 24,505 (9.3%) were other races. As for pathological type, the vast majority (201,369, 76.2%) of the surgically resected samples were infiltrating ductal carcinoma. Infiltrating lobular carcinoma was the second most common pathological type with 19,443 (7.4%) samples. Most tumors (75.0%) presented with a well or moderately differentiated histological grade. The mean NRLNs, NNLNs, LNR, and LODDS were 7.1 ± 7.2, 5.9 ± 6.0, 0.1 ± 0.2 and −0.7 ± 0.5, respectively. Within the NRLNs \<10 subset, the patients' pathological grade tended to be lower, the proportion of stage I patients was higher (25.8% vs 9.1%), and the number of stage III patients was significantly lower (30.5% vs 47.5%). Similarly, the NRLNs \<10 subset is dominated by tumors ≤2 cm in size (71.3%) and an AJCC N stage of N0 (83.6%). These data indicate that tumors in the NRLNs \<10 subset are relatively less malignant than those in the NRLNs ≥10 subset.Table 1Demographic and clinical characteristics of the study cohort.Table 1subset with NRLN \<10\
N = 187,785subset with NRLN≥10\
N = 76,311All Patients\
N = 264,096P-value[c](#tbl1fnc){ref-type="table-fn"}Age at diagnosis, years\<0.001 \<5044,970 (23.9%)24,474 (32.1%)64,305 (26.3%) ≥ 50142,817 (76.1%)51,837 (67.9%)199,791 (73.7%) Median (IQR)59 (50--69)56 (47--66)58 (49--68)Race\<0.001 White154,116 (82.1%)59,336 (77.8%)215,752 (81.2%) Black17,302 (9.2%)10,087 (13.2%)23,839 (9.0%) Others[a](#tbl1fna){ref-type="table-fn"}16,367 (8.7%)6888 (9.0%)24,505 (9.3%)Surgery\<0.001 BCS126,302 (67.3%)49,870 (65.4%)174,936 (66.2%) Mastectomy61,483 (32.7%)26,441 (34.6%)89,160 (33.8%)Histology\<0.001 IDC143,053 (76.2%)57,642 (76.1%)201,369 (76.2%) ILC13,568 (7.2%)6391 (8.4%)19,443 (7.4%) Others[b](#tbl1fnb){ref-type="table-fn"}31,164 (16.6%)12,278 (16.1%)43,284 (16.4%)Grade\<0.001 I48,470 (25.8%)9162 (9.1%)58,337 (22.1%) II82,040 (43.7%)30,907 (40.5%)113,240 (42.9%) III57,275 (30.5%)36,242 (47.5%)92,519 (35.0%)Tumor size (cm)\<0.001 ≤ 2133,852 (71.3%)28,937 (37.9%)164,872 (62.4%) 2--547,745 (25.4%)35,869 (47.0%)83,039 (31.4%) \> 56188 (3.3%)11,505 (15.1%)16,185 (6.1%)AJCC N stage\<0.001 N0157,059 (83.6%)15,990 (21.0%)175,696 (66.5%) N126,867 (14.3%)32,841 (43.0%)62,446 (23.6%) N23502 (14.3%)13,326 (17.5%)17,098 (6.5%) N3357 (0.19%)14,154 (18.5%)8856 (3.4%)NRLN, mean (SD)3.3 (2.2)16.7 (6.0)7.1 (7.2)\<0.001NNLN, mean (SD)3.0 (2.1)13.2 (4.6)5.9 (6.0)\<0.001LNR, mean (SD)0.1 (0.2)0.2 (0.3)0.1 (0.2)\<0.001LODDS, mean (SD)−0.7 (0.4)−0.7 (0.7)−0.7 (0.5)\<0.001ER status\<0.001 Positive154,958 (82.5%)57,418 (75.2%)212,679 (80.5%) Negative32,827 (17.5%)18,893 (24.8%)51,417 (19.5%)PR status\<0.001 Positive135,269 (72.0%)48,830 (64.0%)184,582 (69.9%) Negative52,516 (28.0%)27,481 (36.0%)79,514 (30.1%)Follow-up time Median (IQR)70 (46--100)75 (51--103)73 (50--102)[^2][^3][^4][^5]

The median follow-up time was 73 months (IQR: 50--102). A univariate Cox regression model showed that age, race, tumor size, histological grade, histological subtype, surgery and ER/PR status were significant for OS ([Table 2](#tbl2){ref-type="table"}). As a result of the univariate survival analysis, all the significant variables were included in the Multivariate Cox models.Table 2Univariate Cox proportional hazards model of breast cancer.Table 2All Patients N = 264,096subset with NRLN≥10 N = 76,311subset with NRLN \<10 N = 187,785HR95%CIP valueHR95%CIP valueHR95%CIP valueAge at diagnosisyears \<501.00\<0.0011.00\<0.0011.00\<0.001 ≥501.791.75--1.831.681.62--1.742.212.13--2.30Race White1.00\<0.0011.00\<0.0011.00\<0.001 Black1.521.47--1.561.431.37--1.491.421.36--1.48 Others[a](#tbl2fna){ref-type="table-fn"}0.690.66--0.720.730.68--0.770.630.59--0.67Surgery BCS1.00\<0.0011.00\<0.0011.00\<0.001 Mastectomy2.011.97--2.051.771.71--1.831.741.70--1.79Histology IDC1.00\<0.0011.000.41.000.01 ILC1.051.01--1.091.020.96--1.071.061.00--1.11 Others[b](#tbl2fnb){ref-type="table-fn"}0.960.94--0.990.980.94--1.020.970.93--1.00Grade I1.00\<0.0011.00\<0.0011.00\<0.001 II1.491.44--1.541.411.33--1.501.401.34--1.45 III2.452.38--2.532.292.17--2.432.092.02--2.18Tumor size (cm) ≤ 21.00\<0.0011.00\<0.0011.00\<0.001 2--52.292.25--2.341.981.91--2.052.142.08--2.21 \> 54.314.18--4.443.333.19--3.474.103.90--4.30AJCC N stage N01.00\<0.0011.00\<0.0011.00\<0.001 N11.731.69--1.771.051.00--1.092.011.94--2.07 N23.233.14--3.331.831.74--1.915.234.95--5.52 N35.595.40--5.783.513.35--3.676.445.48--7.58 ER status(P)1.871.83--1.92\<0.0011.851.79--1.91\<0.0011.731.68--1.78 PR status(P)1.831.80--1.87\<0.0011.871.81--1.93\<0.0011.681.63--1.73 LNR5.775.60--5.94\<0.0015.865.60--6.13\<0.0014.434.24--4.62\<0.001 LODDS2.212.18--2.25\<0.0011.951.92--1.99\<0.0012.352.28--2.42\<0.001[^6][^7][^8]

3.2. Relationships between different lymphatic staging systems and prognosis {#sec3.2}
----------------------------------------------------------------------------

The relationships between hazard ratio (HR) and LNR, LODDS, NRLNs and NNLNs were evaluated using the RCS method ([Fig. 2](#fig2){ref-type="fig"}). [Fig. 2](#fig2){ref-type="fig"}A shows the link between LNR and HR, which is nearly linearly related to log~2~HR and has a small confidence interval. When LODDS \< −1, log~2~HR hardly changed, but when the LODDS \> −1, the LODDS had a positive correlation with log~2~HR like LNR ([Fig. 2](#fig2){ref-type="fig"}B). Interestingly, as the NRLNs increase, log~2~HR first increases and then decreases, reaching its highest value at NRLNs = 20 ([Fig. 2](#fig2){ref-type="fig"}C). Finally, we studied the relationship between NNLNs and HR and found the relationship to be negatively correlated ([Fig. 2](#fig2){ref-type="fig"}D). However, the confidence intervals shown in both [Fig. 2](#fig2){ref-type="fig"}C and D are both large, indicating that the accuracy of NRLNs and NNLNs as prognostic factors is deficient.Fig. 2Association between different lymph nodes staging and hazard ratio (HR), allowing for non-linear effects, with 99% CI. A, B, C and D are respectively for lymph node ratio, log odds of metastatic lymph nodes, number of removed lymph nodes and number of negative lymph nodes.Fig. 2

3.3. Impact of the number of removed lymph nodes on the risk of death: is the lymph node ratio an ideal prognostic strategy? {#sec3.3}
----------------------------------------------------------------------------------------------------------------------------

Firstly, we would like to show the reasons why we want to modify LNR. [Fig. 3](#fig3){ref-type="fig"}A illustrates the distribution between the LNR and LODDS. There was a consistent agreement between the LNR and LODDS (Pearson correlation 0.821, P \< 0.001). However, when the value of LNR was equal to 0 (i.e., node-negative patient) or 1, the corresponding LODDS value was quite heterogeneous. In addition, when LNR = 0, the HR of the NRLNs\<10 subset and NRLNs\> 10 subset in the Cox risk regression shown little change. However, when LNR = 1, the HR of the NRLNs\<10 subgroup in the Cox risk regression was significantly lower than that of the NRLNs\>10 subset (HR = 0.606). This result indicates that when the LNR = 1, the ability to predict risk in cases with different NRLNs is significantly heterogeneous. Due to the defect of LNR, we proposed a modified LNR and compared its ability to predict prognosis with NRLNs, LNR and LODDS in different subsets which we will show later.Fig. 3(A) A scatter plot of lymph node ratio (LNR) and log odds of metastatic lymph nodes (LODDS). The distribution shows a one-to-one correspondence and positive correlation between the two curves (except LNR = 1 or LNR = 0 \[node-negative\]). (B) Hazard ratio according to the number of removed lymph nodes examined (NRLN) for different LNR intervals. The hazard ratio varies considerably for a given LNR, especially for LNR \>50%, and increases as the number of removed lymph nodes increases. (C) Hazard ratio according to NRLN for different modified lymph node ratios (mLNR) intervals. The hazard ratio varies little with the increase of NRLN compared with Figure B in different mLNR intervals.Fig. 3

[Fig. 3](#fig3){ref-type="fig"}B and C explain the principle of mLNR. We further explored the interaction between NRLNs and LNR by defining the HR of death associated with the LNR at 4 fixed LNR intervals as 0 \< LNR≤0.25, 0.25 \< LNR≤0.5, 0.5 \< LNR≤0.75 and 0.75 \< LNR ([Fig. 3](#fig3){ref-type="fig"}B). Heterogeneity was noted when analyzing different LNR groups. Although the HR of death was relatively constant for patients with LNR ranging from 0 to 0.25, there was considerable variation in HR when LNR was \>0.50. The HR of death associated with mLNR in the 4 exact fixed mLNR intervals was also calculated ([Fig. 3](#fig3){ref-type="fig"}C). Compared to the LNR curve, the mLNR curve appears smoother and has less heterogeneity. This phenomenon is particularly evident in the mLNR ≥0.5 subset.

3.4. Impact of LN status on risk of death: performance of various LN staging/scoring systems {#sec3.4}
--------------------------------------------------------------------------------------------

Through multivariate Cox models, the LN staging systems with the best prognostic discriminatory ability were assessed through iterative statistical models and compared using the AIC and C-statistic values. [Table 3](#tbl3){ref-type="table"} summarizes the parameter estimates from the multivariate survival analysis that controlled for confounders. When assessed using continuous values among the entire cohort, LNR had a better prognostic performance (C-index: 0.725; AIC: 922505.5) than the LODDS (C-index: 0.720; AIC: 923355.6) and was slightly surpass the AJCC N staging system (C-index: 0.724; AIC: 923546.8) Within the NRLNs \<10 subset, although the performance of LNR (C-index: 0.701; AIC: 501027.1) was better than that of the LODDS (C-index: 0.699; AIC: 501029.3), the performance of LNR was lower than that of the AJCC N staging system (C-index: 0.702; AIC: 500965.3). Within the NRLNs ≥10 subset, the predictive performance of LNR (C-index: 0.719; AIC: 367034) was still better than that of the AJCC N staging system (C-index: 0.712; AIC: 367860.3) but was not better than LODDS (C-index: 0.717; AIC: 367159.9). This finding shows that when the NRLNs \<10, LNR is not ideal as an LN staging system, and it is difficult to predict the OS accurately.Table 3Prognostic performance of the models describing the relationship between different lymph node staging systems and mortality, adjusted for other clinical and demographic variables.Table 3ModelAmong the entire training cohortAmong NRLN\<10 subsetAmong NRLN≥10 subsetOSOSOSAICC-IndexAICC-IndexAICC-Index1- Clinical and demographic Variables (without LN staging systems)9276790.709 (0.706--0.711)502769.50.690 (0.686--0.693)3699720.692 (0.688--0.696)2- Model 1 + AJCC N staging923546.80.724 (0.721--0.726)500965.30.702 (0.698--0.705)367860.30.712 (0.709--0.716)3- Model 1 + LNR (continuous)922505.50.725 (0.722--0.727)500868.50.701 (0.697--0.705)3670340.719 (0.715--0.722)4- Model 1 + mLNR (continuous)922021.90.727 (0.724--0.729)500539.30.702 (0.699--0.706)367036.80.719 (0.715--0.723)5- Model 1 + LODDS (continuous)923355.60.720 (0.717--0.723)501065.10.699 (0.695--0.702)367159.90.717 (0.713--0.720)6- Model 1 + LNR (categorical)922699.40.725 (0.722--0.728)501027.10.701 (0.698--0.705)367353.80.716 (0.712--0.720)7- Model 1 + mLNR (categorical)922351.20.726 (0.723--0.729)500827.70.702 (0.698--0.706)367373.70.717 (0.713--0.720)8- Model 1 + LODDS (categorical)923212.70.724 (0.721--0.726)5011160.698 (0.695--0.702)3673630.715 (0.711--0.719)[^9]

When we adopt the mLNR as the LN staging system, the predictive power of the mLNR is much better than that of the AJCC N staging system, LNR and LODDS among all patients (C-index: 0.725; AIC: 922693.9) and the NRLNs ≥10 subset (C-index: 0.716; AIC: 367373.7). The most important aspect is that the accuracy of the mLNR in the NRLNs \<10 subset (C-index: 0.702; AIC: 500827.7) was similar to that of the AJCC N staging system. All the above data indicate that in our cohort, the predictive performance of mLNR for prognosis is superior to that of other LN staging systems.

To assess whether the relative performance of the different LN staging systems would be impacted by the chosen categorical cutoff values, repeat analyses were performed using categorical variables in the statistical models. Still, mLNR had the best predictive performance, which was higher than LNR, AJCC N staging system and LODDS ([Table 3](#tbl3){ref-type="table"}).

5. Discussion {#sec4}
=============

The LN staging system of breast cancer has a crucial influence and helps guide postoperative patient prognosis, treatment and surveillance. The most widely used LN staging method is the AJCC N staging system, but the reliability of this method has been recently questioned by researchers because the system considers only the NPLNs without considering the NRLNs or NNLNs \[[@bib22], [@bib23], [@bib24], [@bib25]\]. Due to the importance of LN status for breast cancer, researchers have proposed a range of different LN staging methods over the past decade \[[@bib15],[@bib26],[@bib27]\]. Early experiences with LNR can be traced back to the 1990s when several authors proposed that LNR had a more precise and comprehensive prognostic value than NPLNs in patients with resected gastric cancer \[[@bib28], [@bib29], [@bib30]\]. Furthermore, LNR has also been widely studied as a prognostic factor in breast cancer \[[@bib31],[@bib32]\]. However, studies using the LODDS emerged from the cancer research field approximately two decades after recognizing the prognostic utility of the LNR \[[@bib33]\].

In our article, we found that there is a deficiency in LNR. To explore the relationship between the LODDS and LNR, this article studied the scatter plot between LNR and LODDS. As shown in [Fig. 2](#fig2){ref-type="fig"}, there is a high degree of consistency between the LNR and LODDS. However, when LNR = 0 or LNR = 1, the LODDS value becomes extremely heterogeneous. This finding shows that the accuracy of the predictive power for prognosis is significantly reduced when the LNR equals 0 or 1. For an extreme example, the prognosis of a patient with 1 LN removed and 1 positive LN is clearly expected to have a better prognosis than patients with 20 LNs removed and 20 positive LNs.

Based on the above results, we have proposed a modified LNR to improve the predictive power of LNR. We add 2 to the NRLNs, the denominator of LNR to adjust the value of LNR under different NRLNs. Our results show that when utilized as categorical variables, both LNR and LODDS are superior to the traditional AJCC N staging system. However, in the NRLNs\<10 subgroup, the prognostic predictive ability of both LODDS and LNR was slightly lower than that of the AJCC N staging system. Moreover, the predictive power of LODDS and LNR were basically equal to each other, which is different from the results shown in previous studies \[[@bib11]\]. For the NRLNs ≥10 subgroup, both LNR and LODDS were found to be significantly better than the AJCC N staging system, and the predictive power of LNR was better than that of LODDS. It is worth mention that when mLNR was added to the comparison, the data indicated that within the overall patient group or the NRLNs \<10 subgroup, mLNR showed superior predictive power over LNR, LODDS and AJCC N staging system. In addition, within the NRLNs ≥10 subgroup, the predictive power of the mLNR was basically equal to LNR. Furthermore, when mLNR was compared as a continuous variable, mLNR was clearly superior to other LN staging systems in our model. Taken together, our results demonstrate that the introduction of mLNR can greatly increase the predictive power of the model, therefore we suggest that mLNR can be considered when performing LN staging.

There are still some disadvantages to our research. As ratio values, LNR and mLNR are not as convenient to calculate as the AJCC N stage, which makes these ratios difficult to popularize and implement in clinical applications. In addition, it is well known that the state of HER2 expression is an important factor, which significantly influences the prognosis of breast cancer. Since HER2 was introduced in the SEER database after 2010, we did not include data after 2010 in order to obtain more information about prognostic events. Therefore, the HER2 expression status is missing in our data and future work should include HER2 expression designed to evaluate whether mLNR still performs better than other LN staging systems.

6. Conclusion {#sec5}
=============

Our results indicate that mLNR shows superiority to LNR and other lymph node staging systems especially in a limited LN harvest cohort, making mLNR the most powerful lymph node staging systems in our data. Therefore, we believe mLNR can be considered in clinical practice.
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[^5]: P-value was calculated with the chi-square test for categorical variables and with the Kruskal-Wallis test for continuous variables.

[^6]: Abbreviations: N, number; HR, hazard ratio; CI, confidence interval; P, positive; NRLN, number of removed lymph nodes; BCS, breast conserving surgery; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PR, progesterone receptor; LNR, lymph node ratio; LODDS, log odds of metastatic lymph nodes.

[^7]: Including American Indian/Alaskan native and Asian/Pacific Islander.

[^8]: Including other breast cancer histology except IDC and ILC.

[^9]: Abbreviations: AJCC, American Joint Committee on Cancer; BCSS, breast cancer-specific survival; LN, lymph node; LNR, lymph node ratio; mLNR, modified lymph node ratio; LODDS, log odds of metastatic lymph nodes; OS, overall survival.
